| Name | CDK2 |
|---|---|
| Synonyms | CDK 2; CDK2; CDK2deltaT; Cell division kinase 2; Cell division protein kinase 2; Cyclin dependent kinase 2; Cyclin dependent kinase 2 isoform 1; D HSCDK2… |
| Name | kinetin |
|---|---|
| CAS |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 9344580 | Schutte B, Nieland L, van Engeland M, Henfling ME, Meijer L, Ramaekers FC: The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics. Exp Cell Res. 1997 Oct 10;236(1):4-15. Similarly, roscovitine, another CDK inhibitor with a 10-fold higher efficiency for both CDK1 and CDK2 as compared to olomoucine, showed the same effects at a 10-fold lower concentration. |
1(0,0,0,1) | Details |
| 16386795 | Travnicek Z, Krystof V, Sipl M: (II) complexes with potent cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: synthesis, characterization, X-ray structures and biological activity. J Inorg Biochem. 2006 Feb;100(2):214-25. Epub 2006 Jan 4. The cytotoxicity of the zinc (II) complexes against human melanoma, sarcoma, leukaemia and carcinoma cell lines has been determined as well as the inhibition of the CDK2/cyclin E kinase. |
1(0,0,0,1) | Details |
| 9841966 | Iseki H, Ko TC, Xue XY, Seapan A, Townsend CM Jr: A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity. J Gastrointest Surg. 1998 Jan-Feb;2(1):36-43. Transition from G1 to S phase of the cell cycle requires activation of cyclin-dependent kinase 2 (Cdk2) which is inhibited by olomoucine and roscovitine. |
1(0,0,0,1) | Details |
| 11237594 | Haidweger E, Novy M, Rotheneder H: Modulation of Sp1 activity by a cyclin A/CDK complex. . J Mol Biol. 2001 Feb 16;306(2):201-12. Addition of olomoucine, a specific inhibitor of CDK2 and CDC2 activity on the other hand reduces the expression of the reporter. |
1(0,0,0,1) | Details |
| 10465404 | Legraverend M, Ludwig O, Bisagni E, Leclerc S, Meijer L, Giocanti N, Sadri R, Favaudon V: Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors. Bioorg Med Chem. 1999 Jul;7(7):1281-93. Optimal inhibitory activity against CDK5, CDK1 and CDK2, with IC50 values of 0.16, 0.45 and 0.65 microM, respectively, was obtained with compound 21 containing a (2R)-pyrrolidin-2-yl- substituent at the C-2 and a 3-iodobenzylamino group at the C-6 of the |
1(0,0,0,1) | Details |
| 19723061 | Wandl S, Wesierska-Gadek J: Is olomoucine, a weak CDK2 inhibitor, able to induce apoptosis in cancer cells?. Ann N Y Acad Sci. 2009 Aug;1171:242-9. |
1(0,0,0,1) | Details |
| 10602500 | David-Pfeuty T: Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells. Oncogene. 1999 Dec 9;18(52):7409-22. |
1(0,0,0,1) | Details |
| 14653808 | Penuelas S, Alemany C, Noe V, Ciudad CJ: The expression of retinoblastoma and Sp1 is increased by low concentrations of cyclin-dependent kinase inhibitors. Eur J Biochem. 2003 Dec;270(24):4809-22. To achieve this, we used the chemical inhibitors roscovitine and olomoucine (which inhibit CDK2 preferentially), UCN-01 (which also inhibits CDK4/6) and p21 (as an intrinsic inhibitor). |
1(0,0,0,1) | Details |
| 17975794 | Wesierska-Gadek J, Gueorguieva M, Kramer MP, Ranftler C, Sarg B, Lindner H: A new, unexpected action of olomoucine, a CDK inhibitor, on normal human cells: up-regulation of CLIMP-63, a cytoskeleton-linking membrane protein. J Cell Biochem. 2007 Dec 15;102(6):1405-19. The present article shows that olomoucine (OLO), a weak CDK2 inhibitor has new, unexpected activity. |
1(0,0,0,1) | Details |
| 12767603 | Kim DC, Lee YR, Yang BS, Shin KJ, Kim DJ, Chung BY, Yoo KH: Synthesis and biological evaluations of pyrazolo [3,4-d] pyrimidines as cyclin-dependent kinase 2 inhibitors. Eur J Med Chem. 2003 May;38(5):525-32. |
6(0,0,0,6) | Details |
| 9552391 | Kim SH, Schulze-Gahmen U, Brandsen J, de Azevedo Junior WF: Structural basis for chemical inhibition of CDK2. . Prog Cell Cycle Res. 1996;2:137-45. |
3(0,0,0,3) | Details |
| 7479711 | Schulze-Gahmen U, Brandsen J, Jones HD, Morgan DO, Meijer L, Vesely J, Kim SH: Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins. 1995 Aug;22(4):378-91. We describe the crystal structures of the complexes of CDK2 with a weakly specific CDK inhibitor, N6-(delta 2-isopentenyl) and a strongly specific inhibitor, olomoucine. |
3(0,0,0,3) | Details |
| 9828096 | Alessi F, Quarta S, Savio M, Riva F, Rossi L, Stivala LA, Scovassi AI, Meijer L, Prosperi E: The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity. Exp Cell Res. 1998 Nov 25;245(1):8-18. |
3(0,0,0,3) | Details |
| 10884382 | Jin YH, Yoo KJ, Lee YH, Lee SK: Caspase 3-mediated cleavage of p21WAF1/CIP1 associated with the cyclin A-cyclin-dependent kinase 2 complex is a prerequisite for apoptosis in SK-HEP-1 cells. J Biol Chem. 2000 Sep 29;275(39):30256-63. |
2(0,0,0,2) | Details |
| 11896531 | Vermeulen K, Strnad M, Krystof V, Havlicek L, Van der Aa A, Lenjou M, Nijs G, Rodrigus I, Stockman B, van Onckelen H, Van Bockstaele DR, Berneman ZN: Antiproliferative effect of plant cytokinin analogues with an inhibitory activity on cyclin-dependent kinases. Leukemia. 2002 Mar;16(3):299-305. In this study, analogues of olomoucine, a previously described plant cytokinin analogue with cyclin-dependent kinase (CDK) inhibitory activity, were investigated for effect on CDK1 and CDK2 and for effect on cell proliferation. |
2(0,0,0,2) | Details |
| 10495356 | Gray N, Detivaud L, Doerig C, Meijer L: ATP-site directed inhibitors of cyclin-dependent kinases. . Curr Med Chem. 1999 Sep;6(9):859-75. They also play a role in apoptosis (CDK2), in neuronal cells (CDK5) and in the control of transcription (CDK 7, 8, 9). |
2(0,0,0,2) | Details |
| 18761330 | Wesierska-Gadek J, Hajek SB, Sarg B, Wandl S, Walzi E, Lindner H: Pleiotropic effects of selective CDK inhibitors on human normal and cancer cells. Biochem Pharmacol. 2008 Dec 1;76(11):1503-14. Epub 2008 Aug 12. Recently synthesized CKIs, e.g., derivatives such as olomoucine (OLO) and roscovitine (ROSC) are non-genotoxic and exhibit increased selectivity towards CDK2 and CDK7/9. |
1(0,0,0,1) | Details |
| 16214355 | Dolezal K, Popa I, Krystof V, Spichal L, Fojtikova M, Holub J, Lenobel R, Schmulling T, Strnad M: Preparation and biological activity of 6-benzylaminopurine derivatives in plants and human cancer cells. Bioorg Med Chem. 2006 Feb 1;14(3):875-84. Epub 2005 Oct 7. The compounds were also investigated for their effects on cyclin-dependent kinase 2 (CDK2) and for antiproliferative properties on cancer and normal cell lines. |
1(0,0,0,1) | Details |
| 16029936 | Sirotkin AV, Grossmann R: The role of protein kinase A and cyclin-dependent (CDC2) kinase in the control of basal and IGF-II-induced proliferation and secretory activity of chicken ovarian cells. Anim Reprod Sci. 2006 Mar;92(1-2):169-81. Epub 2005 Jul 18. The aim of these experiments was to study the role of protein kinase A (PKA), cyclin-dependent kinase 2 (CDC2) and insulin-like growth factor II (IGF-II) in the control of ovarian function in domestic fowl, as well as the role of PKA and CDC2 in mediating the effects of IGF-II on the ovary. |
1(0,0,0,1) | Details |
| 10234573 | Zhang W, Lee JC, Kumar S, Gowen M: ERK pathway mediates the activation of Cdk2 in IGF-1-induced proliferation of human osteosarcoma MG-63 cells. J Bone Miner Res. 1999 Apr;14(4):528-35. The roles of extracellular signal-regulated kinase 1 (ERK1) and cyclin-dependent kinase 2 (Cdk2) kinases in the IGF-1-induced proliferative signaling pathway of human osteosarcoma MG63 cells were investigated using a selective inhibitor of MEK, PD98059, and a Cdk inhibitor, olomoucine. |
1(0,0,0,1) | Details |